TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid

Dupixent; Dupilumab; Sanofi; Regeneron; bullous pemphigoid; FDA approval; type 2 inflammation; autoimmune disease; priority review; orphan drug

Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial

Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor

Ousted ACIP Members Criticize RFK Jr.’s ‘Destabilizing’ Changes to U.S. Vaccine Policy

ACIP; RFK Jr.; vaccine policy; CDC; committee dismissal; public health; vaccine recommendations; destabilizing decisions